MOG-Enzephalomyelitis

Internationale Empfehlungen zu Diagnose und Antikörpertestung

Translated title of the contribution: MOG encephalomyelitis: international recommendations on diagnosis and antibody testing

S. Jarius, F. Paul, O. Aktas, N. Asgari, R. C. Dale, J. de Seze, D. Franciotta, K. Fujihara, A. Jacob, H. J. Kim, I. Kleiter, T. Kümpfel, M. Levy, J. Palace, K. Ruprecht, A. Saiz, C. Trebst, Brian G Weinshenker, B. Wildemann

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Over the past few years, new-generation cell-based assays have demonstrated a robust association of autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis and brainstem encephalitis, as well as with acute disseminated encephalomyelitis (ADEM)-like presentations. Most experts now consider MOG-IgG-associated encephalomyelitis (MOG-EM) a disease entity in its own right, immunopathogenetically distinct from both classic multiple sclerosis (MS) and aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorders (NMOSD). Owing to a substantial overlap in clinicoradiological presentation, MOG-EM was often unwittingly misdiagnosed as MS in the past. Accordingly, increasing numbers of patients with suspected or established MS are currently being tested for MOG-IgG. However, screening of large unselected cohorts for rare biomarkers can significantly reduce the positive predictive value of a test. To lessen the hazard of overdiagnosing MOG-EM, which may lead to inappropriate treatment, more selective criteria for MOG-IgG testing are urgently needed. In this paper, we propose indications for MOG-IgG testing based on expert consensus. In addition, we give a list of conditions atypical for MOG-EM (“red flags”) that should prompt physicians to challenge a positive MOG-IgG test result. Finally, we provide recommendations regarding assay methodology, specimen sampling and data interpretation, and propose for the first time diagnostic criteria for MOG-EM.

Original languageGerman
JournalNervenarzt
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Encephalomyelitis
Immunoglobulin G
Antibodies
Multiple Sclerosis
Acute Disseminated Encephalomyelitis
Aquaporin 4
Neuromyelitis Optica
Myelitis
Optic Neuritis
Encephalitis
Diagnostic Errors
Autoantibodies
Brain Stem
Biomarkers

Keywords

  • Antibody testing
  • Consensus recommendations
  • Diagnosis
  • Multiple sclerosis (MS)
  • Myelin oligodendrocyte glycoprotein (MOG) antibodies
  • Myelitis
  • Neuromyelitis optica spectrum disorders (NMOSD)
  • Optic neuritis (ON)

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health

Cite this

Jarius, S., Paul, F., Aktas, O., Asgari, N., Dale, R. C., de Seze, J., ... Wildemann, B. (Accepted/In press). MOG-Enzephalomyelitis: Internationale Empfehlungen zu Diagnose und Antikörpertestung. Nervenarzt. https://doi.org/10.1007/s00115-018-0607-0

MOG-Enzephalomyelitis : Internationale Empfehlungen zu Diagnose und Antikörpertestung. / Jarius, S.; Paul, F.; Aktas, O.; Asgari, N.; Dale, R. C.; de Seze, J.; Franciotta, D.; Fujihara, K.; Jacob, A.; Kim, H. J.; Kleiter, I.; Kümpfel, T.; Levy, M.; Palace, J.; Ruprecht, K.; Saiz, A.; Trebst, C.; Weinshenker, Brian G; Wildemann, B.

In: Nervenarzt, 01.01.2018.

Research output: Contribution to journalArticle

Jarius, S, Paul, F, Aktas, O, Asgari, N, Dale, RC, de Seze, J, Franciotta, D, Fujihara, K, Jacob, A, Kim, HJ, Kleiter, I, Kümpfel, T, Levy, M, Palace, J, Ruprecht, K, Saiz, A, Trebst, C, Weinshenker, BG & Wildemann, B 2018, 'MOG-Enzephalomyelitis: Internationale Empfehlungen zu Diagnose und Antikörpertestung', Nervenarzt. https://doi.org/10.1007/s00115-018-0607-0
Jarius, S. ; Paul, F. ; Aktas, O. ; Asgari, N. ; Dale, R. C. ; de Seze, J. ; Franciotta, D. ; Fujihara, K. ; Jacob, A. ; Kim, H. J. ; Kleiter, I. ; Kümpfel, T. ; Levy, M. ; Palace, J. ; Ruprecht, K. ; Saiz, A. ; Trebst, C. ; Weinshenker, Brian G ; Wildemann, B. / MOG-Enzephalomyelitis : Internationale Empfehlungen zu Diagnose und Antikörpertestung. In: Nervenarzt. 2018.
@article{47c3980426804824ab78410c1a2180db,
title = "MOG-Enzephalomyelitis: Internationale Empfehlungen zu Diagnose und Antik{\"o}rpertestung",
abstract = "Over the past few years, new-generation cell-based assays have demonstrated a robust association of autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis and brainstem encephalitis, as well as with acute disseminated encephalomyelitis (ADEM)-like presentations. Most experts now consider MOG-IgG-associated encephalomyelitis (MOG-EM) a disease entity in its own right, immunopathogenetically distinct from both classic multiple sclerosis (MS) and aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorders (NMOSD). Owing to a substantial overlap in clinicoradiological presentation, MOG-EM was often unwittingly misdiagnosed as MS in the past. Accordingly, increasing numbers of patients with suspected or established MS are currently being tested for MOG-IgG. However, screening of large unselected cohorts for rare biomarkers can significantly reduce the positive predictive value of a test. To lessen the hazard of overdiagnosing MOG-EM, which may lead to inappropriate treatment, more selective criteria for MOG-IgG testing are urgently needed. In this paper, we propose indications for MOG-IgG testing based on expert consensus. In addition, we give a list of conditions atypical for MOG-EM (“red flags”) that should prompt physicians to challenge a positive MOG-IgG test result. Finally, we provide recommendations regarding assay methodology, specimen sampling and data interpretation, and propose for the first time diagnostic criteria for MOG-EM.",
keywords = "Antibody testing, Consensus recommendations, Diagnosis, Multiple sclerosis (MS), Myelin oligodendrocyte glycoprotein (MOG) antibodies, Myelitis, Neuromyelitis optica spectrum disorders (NMOSD), Optic neuritis (ON)",
author = "S. Jarius and F. Paul and O. Aktas and N. Asgari and Dale, {R. C.} and {de Seze}, J. and D. Franciotta and K. Fujihara and A. Jacob and Kim, {H. J.} and I. Kleiter and T. K{\"u}mpfel and M. Levy and J. Palace and K. Ruprecht and A. Saiz and C. Trebst and Weinshenker, {Brian G} and B. Wildemann",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00115-018-0607-0",
language = "German",
journal = "Der Nervenarzt",
issn = "0028-2804",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - MOG-Enzephalomyelitis

T2 - Internationale Empfehlungen zu Diagnose und Antikörpertestung

AU - Jarius, S.

AU - Paul, F.

AU - Aktas, O.

AU - Asgari, N.

AU - Dale, R. C.

AU - de Seze, J.

AU - Franciotta, D.

AU - Fujihara, K.

AU - Jacob, A.

AU - Kim, H. J.

AU - Kleiter, I.

AU - Kümpfel, T.

AU - Levy, M.

AU - Palace, J.

AU - Ruprecht, K.

AU - Saiz, A.

AU - Trebst, C.

AU - Weinshenker, Brian G

AU - Wildemann, B.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Over the past few years, new-generation cell-based assays have demonstrated a robust association of autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis and brainstem encephalitis, as well as with acute disseminated encephalomyelitis (ADEM)-like presentations. Most experts now consider MOG-IgG-associated encephalomyelitis (MOG-EM) a disease entity in its own right, immunopathogenetically distinct from both classic multiple sclerosis (MS) and aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorders (NMOSD). Owing to a substantial overlap in clinicoradiological presentation, MOG-EM was often unwittingly misdiagnosed as MS in the past. Accordingly, increasing numbers of patients with suspected or established MS are currently being tested for MOG-IgG. However, screening of large unselected cohorts for rare biomarkers can significantly reduce the positive predictive value of a test. To lessen the hazard of overdiagnosing MOG-EM, which may lead to inappropriate treatment, more selective criteria for MOG-IgG testing are urgently needed. In this paper, we propose indications for MOG-IgG testing based on expert consensus. In addition, we give a list of conditions atypical for MOG-EM (“red flags”) that should prompt physicians to challenge a positive MOG-IgG test result. Finally, we provide recommendations regarding assay methodology, specimen sampling and data interpretation, and propose for the first time diagnostic criteria for MOG-EM.

AB - Over the past few years, new-generation cell-based assays have demonstrated a robust association of autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis and brainstem encephalitis, as well as with acute disseminated encephalomyelitis (ADEM)-like presentations. Most experts now consider MOG-IgG-associated encephalomyelitis (MOG-EM) a disease entity in its own right, immunopathogenetically distinct from both classic multiple sclerosis (MS) and aquaporin-4 (AQP4)-IgG-positive neuromyelitis optica spectrum disorders (NMOSD). Owing to a substantial overlap in clinicoradiological presentation, MOG-EM was often unwittingly misdiagnosed as MS in the past. Accordingly, increasing numbers of patients with suspected or established MS are currently being tested for MOG-IgG. However, screening of large unselected cohorts for rare biomarkers can significantly reduce the positive predictive value of a test. To lessen the hazard of overdiagnosing MOG-EM, which may lead to inappropriate treatment, more selective criteria for MOG-IgG testing are urgently needed. In this paper, we propose indications for MOG-IgG testing based on expert consensus. In addition, we give a list of conditions atypical for MOG-EM (“red flags”) that should prompt physicians to challenge a positive MOG-IgG test result. Finally, we provide recommendations regarding assay methodology, specimen sampling and data interpretation, and propose for the first time diagnostic criteria for MOG-EM.

KW - Antibody testing

KW - Consensus recommendations

KW - Diagnosis

KW - Multiple sclerosis (MS)

KW - Myelin oligodendrocyte glycoprotein (MOG) antibodies

KW - Myelitis

KW - Neuromyelitis optica spectrum disorders (NMOSD)

KW - Optic neuritis (ON)

UR - http://www.scopus.com/inward/record.url?scp=85053919111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053919111&partnerID=8YFLogxK

U2 - 10.1007/s00115-018-0607-0

DO - 10.1007/s00115-018-0607-0

M3 - Article

JO - Der Nervenarzt

JF - Der Nervenarzt

SN - 0028-2804

ER -